| Identification | Back Directory | [Name]
H-ARG(NO2)-PNA | [CAS]
85697-89-8 | [Synonyms]
NAPNA
L-Napna
H-ARG(NO2)-PNA
ARGININE(NO2)-PNA HBR
n(g)-nitroarginine-4-nitroanilide
NG-NITRO-L-ARGININE P-NITROANILIDE
Ng-Nitro-L-Arginine Para-Nitroanilide
N(omega)-Nitro-L-arginine p-nitroanilide
nω-nitro-l-arginine p-nitroanilide hydrobromide
N-omega-nitro-L-arginine P-nitroanilide hydrobrom
N-OMEGA-NITRO-L-ARGININE P-NITROANILIDE HYDROBROMID
N-OMEGA-NITRO-L-ARGININE 4-NITROANILIDE HYDROBROMIDE
N-OMEGA-NITRO-L-ARGININE P-NITRO-ANILIDE HYDROBROMIDE
Pentanamide, 2-amino-5-[[imino(nitroamino)methyl]amino]-N-(4-nitrophenyl)-, (2S)- | [Molecular Formula]
C12H17N7O5 | [MDL Number]
MFCD00136755 | [MOL File]
85697-89-8.mol | [Molecular Weight]
339.31 |
| Hazard Information | Back Directory | [Uses]
L-NAPNA is a nitric oxide synthase (NOS) inhibitor with an IC50 of 1.4 μM. L-NAPNA exhibits analgesic effects by inhibiting formalin-induced paw licking behavior in mice (ED50 of 57.2 mg/kg) and suppressing acetic acid-induced abdominal writhing in mice (ED50 of 25 mg/kg). L-NAPNA can be used in research related to central nervous system diseases[1]. | [References]
[1] Babbedge RC, et al. L-NG-nitro arginine p-nitroanilide (L-NAPNA) is anti-nociceptive in the mouse. Neuroreport. 1993 Mar;4(3):307-10. DOI:10.1097/00001756-199303000-00020 |
|
|